BRIMED

BRIMED, based in the Xishan Economic and Technological Development Zone of Wuxi, Jiangsu, manufactures active pharmaceutical ingredients and finished dosage forms centered on products such as tacrolimus, mitomycin, mycophenolate mofetil, netilmicin sulfate, the spiramycin series, ribostamycin sulfate, S-adenosylmethionine, cantharidin and rifapentine, spanning immune-regulating, anti-infective, digestive, respiratory, central nervous system and peptide drug categories. Operating a US FDA cGMP-compliant facility with a dedicated immunogenic finished-dosage line for the European market, the company functions as a full-service CDMO and has passed multiple EU GMP on-site inspections since 2005 (including audits in 2008, 2011, 2013, 2015, 2016 and 2019) as well as an FDA Pre-Approval Inspection in 2023 for its mycophenolate mofetil capsules ANDA project. Roughly 40% of production is exported and 60% sold domestically, with shipment under FOB, CFR, CIF, CIP or DDP terms and payment via L/C, T/T or D/P, reflecting the company's established brand, experienced R&D staff and broad product line.